DEFA14A: Dynavax Urges Stockholders to Vote for Director Nominees Amid Deep Track Capital Challenge

Dynavax is urging stockholders to vote for its four director nominees at the upcoming Annual Meeting, highlighting the Board's role in overseeing significant value creation and dismissing a challenge from Deep Track Capital.

Summary

• Dynavax Technologies Corporation is urging stockholders to vote for its four director nominees at the 2025 Annual Meeting.
• Deep Track Capital is seeking to replace four of Dynavax's independent directors, a move Dynavax believes would be detrimental to long-term value.
• Dynavax highlights its Board's recent refreshment with qualified directors who have enhanced corporate governance and overseen strong financial performance.
• The company emphasizes its successful transformation since 2019, prioritizing its vaccine business and launching HEPLISAV-B.
• Dynavax's Board has overseen a disciplined strategy resulting in a 267% total stockholder return over the past five years.
• HEPLISAV-B generated $268 million in net product revenue in 2024, with a 44% U.S. market share and a 65% compound annual growth rate since 2020.
• The company anticipates HEPLISAV-B net product revenue of $305-$325 million in 2025 and expects the U.S. hepatitis B adult vaccine market to grow to over $900 million in annual sales by 2030.
• Dynavax is developing a shingles vaccine with Phase 1/2 topline results expected in Q3 2025 and a plague vaccine with a Phase 2 trial expected to initiate in Q3 2025.
• The company's CpG 1018 adjuvant commercial supply agreements generated over $950 million in net product revenue from 2020 to 2022.
• Dynavax is executing a $200 million share repurchase program initiated in November 2024, with $128.8 million executed as of the end of Q1 2025.
• The company recently refinanced a majority of its outstanding Convertible Senior Notes, extending the maturity date and lowering the cost of capital.
• Dynavax argues that its director nominees are more qualified than Deep Track's candidates, citing their expertise in biotechnology and vaccine operations.
• Deep Track's plan includes an accelerated share repurchase program of at least $400 million, royalty financing leveraging HEPLISAV-B, and abandoning internal development efforts.
• Dynavax believes Deep Track's plan favors a near-term payoff and would destroy long-term value.

Sentiment

Score: 7

Explanation: The document conveys a positive outlook for Dynavax, highlighting strong financial performance, successful product commercialization, and a promising pipeline. However, the ongoing challenge from Deep Track Capital introduces an element of uncertainty, preventing a higher sentiment score.

Positives

• Dynavax has delivered a 267% total stockholder return over the past five years.
• HEPLISAV-B has shown strong commercial performance, generating $268 million in net product revenue in 2024.
• The company has a promising pipeline, including a shingles vaccine and a plague vaccine in development.
• Dynavax has a disciplined capital strategy, including a $200 million share repurchase program.
• The company has strengthened its capital structure by refinancing its Convertible Senior Notes.

Negatives

• Deep Track Capital is challenging Dynavax's Board and strategy.
• Deep Track's proposed plan could potentially disrupt Dynavax's current momentum and long-term value creation.

Risks

• The risk that circumstances surrounding or leading up to our 2025 Annual Meeting may change.
• Risks relating to our ability to commercialize and supply HEPLISAV-B.
• Risks related to the implementation of our long-term growth objectives.

Future Outlook

Dynavax expects 2025 to be a banner year for HEPLISAV-B, with anticipated net product revenue of $305-$325 million. The company also expects longer-term market share leadership in the U.S. hepatitis B adult vaccine market, which is expected to grow to over $900 million in annual sales by 2030. Topline results for the shingles vaccine Phase 1/2 trial are expected in Q3 2025, and the Phase 2 trial for the plague vaccine is expected to initiate in Q3 2025.

Management Comments

• The Dynavax Board of Directors has been meaningfully refreshed in recent years with qualified directors who have enhanced the Company's corporate governance while overseeing consistent and record financial and operational performance.
• Dynavax is in the strongest position it has ever been in, and our Board's nominees are essential to advancing Dynavax's strategy and driving long-term stockholder value at this pivotal juncture for the Company.
• Our Board refreshment process has always been driven by a clear set of criteria based on Dynavax's current and future needs.

Industry Context

The announcement comes as Dynavax faces a challenge from Deep Track Capital, highlighting the increasing activist investor activity in the biopharmaceutical sector. The focus on long-term value creation versus short-term gains is a common theme in such situations. Dynavax's emphasis on its vaccine pipeline and commercial success with HEPLISAV-B positions it within the competitive landscape of vaccine developers and manufacturers.

Comparison to Industry Standards

• Dynavax's total stockholder return of 267% over the past five years exceeds the performance of the NASDAQ Biotechnology Index and the S&P Biotechnology Select Industry Index.
• HEPLISAV-B's 44% U.S. market share in 2024 demonstrates its competitive position against other hepatitis B vaccines.
• The company's development of a shingles vaccine aims to disrupt a $4.4 billion global market, competing with established players like GSK's Shingrix and Merck's Zostavax (now discontinued).
• The plague vaccine program addresses an unmet need, as there is currently no approved vaccine in the U.S., potentially giving Dynavax a first-mover advantage.

Stakeholder Impact

• Shareholders are urged to vote to protect their investment and ensure continued value creation.
• Employees' jobs and the company's future success depend on the outcome of the vote.
• Customers will benefit from the continued development and commercialization of innovative vaccines.

Next Steps

• Stockholders are urged to vote FOR Dynavax's four director nominees on the GOLD universal proxy card.
• The Annual Meeting will be held on June 11, 2025.
• Topline results for the shingles vaccine Phase 1/2 trial are expected in Q3 2025.
• The Phase 2 trial for the plague vaccine is expected to initiate in Q3 2025.

Key Dates

Keywords

Dynavax, HEPLISAV-B, Board of Directors, Deep Track Capital, Annual Meeting, Vaccine, Stockholder Value, Share Repurchase, Director Nominees, Corporate Governance